An eye-treatment trial missed its main goal; EyePoint plans to cut about 53% of jobs.
An eye-treatment trial missed its main goal; EyePoint plans to cut about 53% of jobs. Stock Titan
Covered in this story
Call it yourself
No calls on $EYPT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Eyepoint Inc →Summary aggregated from Stock Titan's public RSS feed. The full reporting belongs to Stock Titan — please read it on their site.